Novo Nordisk will cut 9,000 jobs which is about 11.5% of its global workforce with 5,000 roles in Denmark. This forms part of a restructuring aimed at speeding decisions and redirecting spending to core obesity and diabetes drugs.
The move follows months of pressure in the weight-loss market and an August hiring freeze on non-critical roles. The company targets DKK 8 billion (~$1.25B) in annual savings.
Management expects a DKK 9bn one-off restructuring charge in Q3 and DKK 1bn of savings already in Q4. Novo also cut its 2025 operating-profit growth outlook to 4%–10%, down from the 19%–27% range at the start of the year, citing costs and a tougher U.S. market.
The overhaul is one of the first major steps under Maziar Mike Doustdar, appointed president and CEO effective Aug. 7, 2025. The company said the changes are meant to simplify operations and “instill a performance-based culture.”
Competitive backdrop
U.S. rival Eli Lilly continues to expand share with tirzepatide (sold as Mounjaro for diabetes and Zepbound for obesity) and posted 38% year-over-year revenue growth in Q2 2025, driven by its incretin franchise.
That momentum, plus the crackdown on compounded “copycat” GLP-1s, has reshaped the category and intensified price and access battles.
Policy and pricing context
A fresh ICER analysis says GLP-1 treatments Wegovy (semaglutide) and Zepbound (tirzepatide) look more cost-effective than in earlier reviews, aided by price changes and stronger outcomes data. That may support coverage decisions, though budget impact remains a constraint.
Novo says savings will be reinvested in R&D, manufacturing and market access for its obesity and diabetes portfolio, including Wegovy and Ozempic. The company frames the cuts as removing layers and speeding launches rather than reducing production capacity.
Market reaction and next checks
Shares whipsawed on the news, with early losses turning to gains intraday, as investors weighed near-term charges against longer-term savings and sharper focus. Key markers over the next two quarters: steadier U.S. prescription trends post-compounding crackdown, delivery-device and fill-finish capacity updates, and clarity on payer coverage into 2026.
The layoffs are a defensive reset to protect Novo’s position in a fast-maturing GLP-1 market. The math works only if savings translate into cleaner execution, supply reliability and competitive next-gen readouts.
